Sanofi India (500674) Q3 2025 earnings summary

Executive summary

• Underwent a major business transformation in 2025, focusing on diabetes and insulin, modernizing the business model for sustainable, profitable growth, and shifting legacy cardiovascular, CNS, and oral antidiabetic drugs to a partnership model.

• Digitally empowered teams and adopted AI-driven tools to enhance customer centricity, operational efficiency, and market reach, especially in Tier II/III cities.

• Strategic focus on innovative diabetes products like Toujeo and Soliqua, with market expansion initiatives and public sector engagement.

• Unaudited financial statements for the quarter and nine months ended September 30, 2025, were approved by the Board on October 29, 2025.

• Interim dividend of ₹75 per equity share declared for 2025, with a record date of November 7, 2025.

Financial highlights

• Diabetes segment grew 4% YTD September 2025 and 5% quarter-over-quarter; domestic sales grew 3% YTD and 2% in Q3 2025.

• Export sales declined 35% YTD and 45% in Q3 2025 year-over-year, impacted by Ankleshwar site divestment and regulatory delays, but new markets like Russia and South Africa are being targeted.

• Operating expenses as a percentage of net sales improved to 22% in Q3 2025 from 26% in Q1 2025.

• Net sales margin and PBT margin improved to 29% in Q3 2025, with profit before tax up 15% year-over-year.

• Nine-month profit from continuing operations was ₹2,650 million, up from ₹2,224 million year-over-year.

Outlook and guidance

• Focus remains on accelerating diabetes performance, especially with Toujeo and Soliqua, leveraging AI for future growth, and prioritizing organic growth from the current portfolio.

• Margins expected to remain stable or improve due to ongoing OpEx optimization and operational excellence.

• No major new product launches expected in 2026.